Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 14/20 | 0.69 |
| ▸ | THRB | P10828 | 14/20 | 0.69 |
| ▸ | EGLN1 | Q9GZT9 | 9/20 | 0.69 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.65 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | ASPH | Q12797 | 1/20 | 0.56 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.56 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30004549 | 1.00 | THRA (0.69) | THRATHRBEGLN1BBOX1FTO | |
| SCHEMBL1509116 | 0.96 | THRA (0.75) | THRATHRBEGLN1BBOX1FTO | |
| SCHEMBL30004356 | 0.96 | THRA (0.75) | THRATHRBEGLN1BBOX1FTO | |
| SCHEMBL4081493 | 0.89 | THRA (0.56) | THRATHRBEGLN1BBOX1FTO | |
| SCHEMBL522875 | 0.88 | THRA (0.64) | THRATHRBEGLN1BBOX1FTO | |
| SCHEMBL31028948 | 0.88 | THRA (0.64) | THRATHRBEGLN1BBOX1FTO | |
| SCHEMBL522871 | 0.87 | EGLN1 (0.49) | THRATHRBEGLN1BBOX1FTO | |
| SCHEMBL523521 | 0.86 | THRA (0.91) | THRATHRBEGLN1BBOX1FTO | |
| SCHEMBL1656320 | 0.85 | EGLN2 (0.75) | EGLN1EGLN2 | |
| SCHEMBL4075898 | 0.85 | THRA (0.55) | THRATHRBEGLN1BBOX1FTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080425-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. (US) | 2015-03-19 | — | — | US | claimed |
| EP-1463823-B1 | METHODS OF INCREASING ENDOGENOUS ERYTHROPOIETIN (EPO) | FIBROGEN INC (US) | 2013-03-06 | — | — | EP | claimed |
| US-20060178316-A1 | Methods of increasing endogenous erythropoietin (EPO) | FIBROGEN, INC. (US) | 2006-08-10 | — | — | US | claimed |
| EP-2298301-B2 | MEDICAMENTS FOR TREATING ANEMIA ASSOCIATED WITH KIDNEY DISEASE | FIBROGEN INC (US) | 2022-11-16 | — | — | EP | disclosed |
| US-20210369702-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. (US) | 2021-12-02 | — | — | US | disclosed |
| EP-3520784-A1 | HIF PROLYL HYDROXYLASE INHIBITOR FOR TREATMENT OF ANEMIA | Fibrogen, Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-2324834-B1 | Methods of Increasing Endogenous Erythropoietin (EPO) | FIBROGEN INC (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-2298301-B1 | MEDICAMENTS FOR TREATING ANEMIA ASSOCIATED WITH KIDNEY DISEASE | FIBROGEN INC (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-2289531-B1 | Medicaments for the treatment or prevention of anemia | FIBROGEN INC (US) | 2018-07-04 | — | — | EP | disclosed |
| US-20170312268-A1 | METHODS FOR TREATING A NEUROLOGICAL DISORDER IN A SUBJECT USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) PROYL HYDROXYLASE | FIBROGEN, INC. (US) | 2017-11-02 | — | — | US | disclosed |
| US-20150080425-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20060178317-A1 | Methods of increasing endogenous erythropoietin (EPO) | FIBROGEN, INC. (US) | 2006-08-10 | — | — | US | disclosed |
| EP-1463823-A4 | METHODS OF INCREASING ENDOGENOUS ERYTHROPOIETIN (EPO) | FIBROGEN INC (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-0911340-B1 | Substituted Isoquinolin-3-Carboxyamides, their preparation and medical use | FIBROGEN INC (US) | 2005-07-06 | — | — | EP | disclosed |
| EP-1538160-A1 | Substituted Isoquinolin-3-carboxyamides, their preparation and medical use | FIBROGEN, INC. (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1463823-A2 | METHODS OF INCREASING ENDOGENOUS ERYTHROPOIETIN (EPO) | FIBROGEN, INC. (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030153503-A1 | Methods of increasing endogenous erythropoietin (EPO) | FIBROGEN, INC. | 2003-08-14 | — | — | US | disclosed |
| WO-2003053997-A2 | METHODS OF INCREASING ENDOGENOUS ERYTHROPOIETIN (EPO) | FIBROGEN, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
| US-6093730-A | AN ENZYME INHIBITORS OF PROLYL-4-HYDROXYLASE FOR TREATING FIBROTIC DISORDERS AND INHIBITING COLLAGEN BIOSYNTHESIS | HOECHST MARION ROUSSEL DEUTSCHLAND GMBH (DE) | 2000-07-25 | — | — | US | disclosed |
| EP-0911340-A2 | Substituted Isoquinolin-3-Carboxyamides, their preparation and medical use | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080425-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | THRA 1520/4885THRB 1669/4885EGLN1 5/4885 |
| US-20060178317-A1 | Methods of increasing endogenous erythropoietin (EPO) | EPOR, EGLN3, EGLN2 | THRA 2906/4885THRB 2553/4885EGLN1 13/4885 |
| US-20210369702-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | THRA 1520/4885THRB 1669/4885EGLN1 5/4885 |
| US-20170312268-A1 | METHODS FOR TREATING A NEUROLOGICAL DISORDER IN A SUBJECT USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) PROYL HYDROXYLASE | HIF1AN, EGLN2, EGLN3 | THRA 2211/4885THRB 2231/4885EGLN1 9/4885 |
| US-20030153503-A1 | Methods of increasing endogenous erythropoietin (EPO) | EPOR, EGLN3, EGLN2 | THRA 2906/4885THRB 2553/4885EGLN1 13/4885 |
| US-20060178316-A1 | Methods of increasing endogenous erythropoietin (EPO) | EPOR, EGLN3, EGLN2 | THRA 2906/4885THRB 2553/4885EGLN1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.